Drugs / WHG626
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04123418 | Dec 2019 → Dec 2024 | plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WHG626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04123418 ↗ |
| Route | Oral | “WHG626 will be administered orally in a dose escalation schedule” NCT04123418 ↗ |